Loading
Life sciences · Review
Journal of International Medical Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Polycythemia vera is a chronic myeloproliferative neoplasm in which erythrocytosis, Janus kinase–signal transducer and activator of transcription activation, inflammation, endothelial dysfunction, and abnormal blood–cell activation converge to increase cardiovascular risk. This narrative review examines how electrocardiography, echocardiography, coronary angiography, cardiac magnetic resonance imaging, and right-heart catheterization contribute to recognition and characterization of cardiac involvement in polycythemia vera. Reported abnormalities include QT and P-wave changes, atrial arrhythmias, acute coronary syndromes, subclinical biventricular dysfunction, pulmonary hypertension, intracardiac thrombosis, and hypertrophic remodeling. Large observational datasets in myeloproliferative neoplasms also exhibit clinically important burdens of myocardial infarction, heart-failure hospitalization, bleeding, and echocardiographic pulmonary hypertension, although polycythemia vera–specific estimates remain limited. Baseline cardiovascular testing is increasingly relevant before novel therapies and trial enrollment; however, an abnormal test should prompt confirmation, reversible-cause assessment, and protocol-specific review rather than be treated as a universal contraindication. Hematocrit control and low-dose aspirin reduce thrombotic events, while evidence that cytoreductive therapy reverses electrocardiography or imaging abnormalities remains sparse. A symptom- and risk-directed diagnostic approach, integrated with hematology and cardiology assessment, is therefore more defensible than routine universal cardiac screening.